1
|
Barloy L, Heinrich B, Scarpi-Luttenauer M, Douce L, Henry M, Khalil G, Klein D, Kyritsakas N, Mobian P. Modified pyridine-triazole and 2,2'-bipyrimidine ligands generating robust titanium complexes constructed around a TiO 4N 2 core. Dalton Trans 2021; 50:17008-17022. [PMID: 34738604 DOI: 10.1039/d1dt03172d] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
The synthesis and characterisation of novel chelate nitrogen ligands with phasmidic tails (pyridine-triazole ligand 1b; 2,2'-bipyrimidine ligands 2b and 3b) as well as their titanium(IV) coordination complexes are reported. The analogous ligands 1a, 2a and 3a with methoxy substituents instead of the tails were also synthesized, together with titanium complexes that could be crystallographically characterised. A good agreement is noticed between analytical data of the complexes in solution (NMR) and in the solid state (X-ray diffraction). The complexes are overall robust on phases like alumina or silica, so that they could be characterised by TLC and sometimes chromatographied. Supramolecular architectures were generated from an equimolar solution of titanium(IV) isopropoxide, ligand 1a and a polyphenol ligand 5-H4, leading to a double-stranded helicate characterised by MS, NMR and crystallography, which was then converted into a trinuclear complex as shown by MS and NMR DOSY data. The liquid-crystalline behaviour of the ligands 1b, 2b and 3b incorporating the long alkyl tails and that of the complexes derived from these ligands have been investigated.
Collapse
Affiliation(s)
- L Barloy
- Université de Strasbourg, CNRS, CMC UMR 7140, F-67000 Strasbourg, France.
| | - B Heinrich
- Institut de Physique et Chimie des Matériaux de Strasbourg (IPCMS), UMR 7504, CNRS-Université de Strasbourg, F-67034 Strasbourg, France
| | | | - L Douce
- Institut de Physique et Chimie des Matériaux de Strasbourg (IPCMS), UMR 7504, CNRS-Université de Strasbourg, F-67034 Strasbourg, France
| | - M Henry
- Université de Strasbourg, CNRS, CMC UMR 7140, F-67000 Strasbourg, France.
| | - G Khalil
- Université de Strasbourg, CNRS, CMC UMR 7140, F-67000 Strasbourg, France.
| | - D Klein
- Université de Strasbourg, CNRS, CMC UMR 7140, F-67000 Strasbourg, France.
| | - N Kyritsakas
- Université de Strasbourg, CNRS, CMC UMR 7140, F-67000 Strasbourg, France.
| | - P Mobian
- Université de Strasbourg, CNRS, CMC UMR 7140, F-67000 Strasbourg, France.
| |
Collapse
|
2
|
Barloy L, Heinrich B, Douce L, Henry M, Scarpi-Luttenauer M, Kyritsakas N, Mobian P. A robust Ti(iv)-based mesogen constructed around a TiO4N2 core. Dalton Trans 2019; 48:1960-1963. [DOI: 10.1039/c8dt04972f] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
A Ti(iv)-complex with thermotropic liquid crystal properties is reported.
Collapse
Affiliation(s)
- L. Barloy
- Laboratoire de Chimie Moléculaire de l'Etat Solide
- UMR 7140 UDS-CNRS
- Université de Strasbourg
- F-67000 Strasbourg
- France
| | - B. Heinrich
- Université de Strasbourg
- CNRS
- Institut de Physique et de Chimie des Matériaux de Strasbourg
- F-67000 Strasbourg
- France
| | - L. Douce
- Université de Strasbourg
- CNRS
- Institut de Physique et de Chimie des Matériaux de Strasbourg
- F-67000 Strasbourg
- France
| | - M. Henry
- Laboratoire de Chimie Moléculaire de l'Etat Solide
- UMR 7140 UDS-CNRS
- Université de Strasbourg
- F-67000 Strasbourg
- France
| | - M. Scarpi-Luttenauer
- Laboratoire de Chimie Moléculaire de l'Etat Solide
- UMR 7140 UDS-CNRS
- Université de Strasbourg
- F-67000 Strasbourg
- France
| | - N. Kyritsakas
- Laboratoire de Tectonique Moléculaire
- UMR 7140 UDS-CNRS
- Université de Strasbourg
- F-67000 Strasbourg
- France
| | - P. Mobian
- Laboratoire de Chimie Moléculaire de l'Etat Solide
- UMR 7140 UDS-CNRS
- Université de Strasbourg
- F-67000 Strasbourg
- France
| |
Collapse
|
3
|
Affiliation(s)
- S. Nasifoglu
- Department of Dermatology; General Hospital Augsburg; Augsburg Germany
| | - B. Heinrich
- Brudler, Heinrich, Bangerter Haematologic-Oncological Practice; Augsburg Germany
| | - J. Welzel
- Department of Dermatology; General Hospital Augsburg; Augsburg Germany
| |
Collapse
|
4
|
Heinrich B, Klein J, Delic M, Goepfert K, Engel V, Geberzahn L, Lusky M, Erbs P, Preville X, Moehler M. Immunogenicity of oncolytic vaccinia viruses JX-GFP and TG6002 in a human melanoma in vitro model: studying immunogenic cell death, dendritic cell maturation and interaction with cytotoxic T lymphocytes. Onco Targets Ther 2017; 10:2389-2401. [PMID: 28496337 PMCID: PMC5422459 DOI: 10.2147/ott.s126320] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
Oncolytic virotherapy is an emerging immunotherapeutic modality for cancer treatment. Oncolytic viruses with genetic modifications can further enhance the oncolytic effects on tumor cells and stimulate antitumor immunity. The oncolytic vaccinia viruses JX-594-GFP+/hGM-CSF (JX-GFP) and TG6002 are genetically modified by secreting granulocyte-macrophage colony-stimulating factor (GM-CSF) or transforming 5-fluorocytosine (5-FC) into 5-fluorouracil (5-FU). We compared their properties to kill tumor cells and induce an immunogenic type of cell death in a human melanoma cell model using SK29-MEL melanoma cells. Their influence on human immune cells, specifically regarding the activation of dendritic cells (DCs) and the interaction with the autologous cytotoxic T lymphocyte (CTL) clone, was investigated. Melanoma cells were infected with either JX-GFP or TG6002 alone or in combination with 5-FC and 5-FU. The influence of viral infection on cell viability followed a time- and multiplicity of infection dependent manner. Combination of virus treatment with 5-FU resulted in stronger reduction of cell viability. TG6002 in combination with 5-FC did not significantly strengthen the reduction of cell viability in this setting. Expression of calreticulin and high mobility group 1 protein (HMGB1), markers of immunogenic cell death (ICD), could be detected after viral infection. Accordingly, DC maturation was noted after viral oncolysis. DCs presented stronger expression of activation and maturation markers. The autologous CTL clone IVSB expressed the activation marker CD69, but viral treatment failed to enhance cytotoxicity marker. In summary, vaccinia viruses JX-GFP and TG6002 lyse melanoma cells and induce additional immunostimulatory effects to promote antitumor immune response. Further investigation in vivo is needed to consolidate the data.
Collapse
Affiliation(s)
- B Heinrich
- First Department of Internal Medicine, University Medical Center Mainz, Mainz, Germany
| | - J Klein
- First Department of Internal Medicine, University Medical Center Mainz, Mainz, Germany
| | - M Delic
- First Department of Internal Medicine, University Medical Center Mainz, Mainz, Germany
| | - K Goepfert
- First Department of Internal Medicine, University Medical Center Mainz, Mainz, Germany
| | - V Engel
- First Department of Internal Medicine, University Medical Center Mainz, Mainz, Germany
| | - L Geberzahn
- First Department of Internal Medicine, University Medical Center Mainz, Mainz, Germany
| | - M Lusky
- Transgene SA, Illkirch-Graffenstaden
| | - P Erbs
- Transgene SA, Illkirch-Graffenstaden
| | | | - M Moehler
- First Department of Internal Medicine, University Medical Center Mainz, Mainz, Germany
| |
Collapse
|
5
|
Singer P, Wirth M, Berger I, Heinrich B, Gödicke W, Voigt S, Taube C, Jaross W, Gehrisch S. Long-chain omega 3 fatty acids are the most effective polyunsaturated fatty acids for dietary prevention and treatment of cardiovascular risk factors. Conclusions from clinical studies. World Rev Nutr Diet 2015; 69:74-112. [PMID: 1441585 DOI: 10.1159/000421667] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Affiliation(s)
- P Singer
- Central Institute for Cardiovascular Research, Academy of Sciences, Berlin-Buch, FRG
| | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Reck M, Thomas M, Schuette W, Kimmich M, Rittmeyer A, Heinrich B, Yurasov S, Zimmermann A, Carter GC, Garon EB, Pérol M. Update REVEL: Eine randomisierte, doppelblinde Phase III Studie von Docetaxel (DOC) und Ramucirumab (RAM; IMC-1121B) versus DOC und Placebo (PL) in der Zweitlinienbehandlung des Nicht-Kleinzelligen Lungenkarzinoms im Stadium IV nach Progression der Erkrankung nach einer Platin-basierten Vortherapie. Pneumologie 2015. [DOI: 10.1055/s-0035-1544764] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
7
|
Charlon M, Heinrich B, Matter Y, Couzigné E, Donnio B, Avérous L. Synthesis, structure and properties of fully biobased thermoplastic polyurethanes, obtained from a diisocyanate based on modified dimer fatty acids, and different renewable diols. Eur Polym J 2014. [DOI: 10.1016/j.eurpolymj.2014.10.012] [Citation(s) in RCA: 50] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
8
|
von Minckwitz G, Loibl S, Untch M, Eidtmann H, Rezai M, Fasching PA, Tesch H, Eggemann H, Schrader I, Kittel K, Hanusch C, Huober J, Solbach C, Jackisch C, Kunz G, Blohmer JU, Hauschild M, Fehm T, Nekljudova V, Gerber B, Gnauert K, Heinrich B, Prätz T, Groh U, Tanzer H, Villena C, Tulusan A, Liedtke B, Blohmer JU, Kittel K, Mau C, Potenberg J, Schilling J, Just M, Weiss E, Bückner U, Wolfgarten M, Lorenz R, Doering G, Feidicker S, Krabisch P, Deichert U, Augustin D, Kunz G, Kast K, von Minckwitz G, Nestle-Krämling C, Rezai M, Höß C, Terhaag J, Fasching P, Staib P, Aktas B, Kühn T, Khandan F, Möbus V, Solbach C, Tesch H, Stickeler E, Heinrich G, Wagner H, Abdallah A, Dewitz T, Emons G, Belau A, Rethwisch V, Lantzsch T, Thomssen C, Mattner U, Nugent A, Müller V, Noesselt T, Holms F, Müller T, Deuker JU, Schrader I, Strumberg D, Uleer C, Solomayer E, Runnebaum I, Link H, Tomé O, Ulmer HU, Conrad B, Feisel-Schwickardi G, Eidtmann H, Schumacher C, Steinmetz T, Bauerfeind I, Kremers S, Langanke D, Kullmer U, Ober A, Fischer D, Kohls A, Weikel W, Bischoff J, Freese K, Schmidt M, Wiest W, Sütterlin M, Dietrich M, Grießhammer M, Burgmann DM, Hanusch C, Rack B, Salat C, Sattler D, Tio J, von Abel E, Christensen B, Burkamp U, Köhne CH, Meinerz W, Graßhoff ST, Decker T, Overkamp F, Thalmann I, Sallmann A, Beck T, Reimer T, Bartzke G, Deryal M, Weigel M, Huober J, Weder P, Steffens CC, Lemster S, Stefek A, Ruhland F, Hofmann M, Schuster J, Simon W, Kronawitter U, Clemens M, Fehm T, Janni W, Latos K, Bauer W, Roßmann A, Bauer L, Lampe D, Heyl V, Hoffmann G, Lorenz-Salehi F, Hackmann J, Schlag R. Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)†. Ann Oncol 2014; 25:2363-2372. [PMID: 25223482 DOI: 10.1093/annonc/mdu455] [Citation(s) in RCA: 97] [Impact Index Per Article: 9.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND The GeparQuinto study showed that adding bevacizumab to 24 weeks of anthracycline-taxane-based neoadjuvant chemotherapy increases pathological complete response (pCR) rates overall and specifically in patients with triple-negative breast cancer (TNBC). No difference in pCR rate was observed for adding everolimus to paclitaxel in nonearly responding patients. Here, we present disease-free (DFS) and overall survival (OS) analyses. PATIENTS AND METHODS Patients (n = 1948) with HER2-negative tumors of a median tumor size of 4 cm were randomly assigned to neoadjuvant treatment with epirubicin/cyclophosphamide followed by docetaxel (EC-T) with or without eight infusions of bevacizumab every 3 weeks before surgery. Patients without clinical response to EC ± Bevacizumab were randomized to 12 weekly cycles paclitaxel with or without everolimus 5 mg/day. To detect a hazard ratio (HR) of 0.75 (α = 0.05, β = 0.8) 379 events had to be observed in the bevacizumab arms. RESULTS With a median follow-up of 3.8 years, 3-year DFS was 80.8% and 3-year OS was 89.7%. Outcome was not different for patients receiving bevacizumab (HR 1.03; P = 0.784 for DFS and HR 0.974; P = 0.842 for OS) compared with patients receiving chemotherapy alone. Patients with TNBC similarly showed no improvement in DFS (HR = 0.99; P = 0.941) and OS (HR = 1.02; P = 0.891) when treated with bevacizumab. No other predefined subgroup (HR+/HER2-; locally advanced (cT4 or cN3) or not; cT1-3 or cT4; pCR or not) showed a significant benefit. No difference in DFS (HR 0.997; P = 0.987) and OS (HR 1.11; P = 0.658) was observed for nonearly responding patients receiving paclitaxel with or without everolimus overall as well as in subgroups. CONCLUSIONS Long-term results, in opposite to the results of pCR, do not support the neoadjuvant use of bevacizumab in addition to an anthracycline-taxane-based chemotherapy or everolimus in addition to paclitaxel for nonearly responding patients. CLINICAL TRIAL NUMBER NCT 00567554, www.clinicaltrials.gov.
Collapse
Affiliation(s)
- G von Minckwitz
- Headquarter, German Breast Group, Neu-Isenburg; Department of Gynaecology and Obstetrics, University Hospital, Frankfurt.
| | - S Loibl
- Headquarter, German Breast Group, Neu-Isenburg
| | - M Untch
- Department of Gynaecology and Obstetrics, Klinikum Berlin-Buch, Berlin
| | - H Eidtmann
- Department of Gynaecology and Obstetrics, University Hospital, Kiel
| | - M Rezai
- Breast Center, Luisenkrankenhaus, Düsseldorf
| | - P A Fasching
- Department of Gynaecology and Obstetrics, University Hospital, Erlangen
| | - H Tesch
- Department of Medical Oncology, Chop GmbH, Frankfurt
| | - H Eggemann
- Department of Gynaecology and Obstetrics, University Hospital, Magdeburg
| | - I Schrader
- Department of Gynaecology and Obstetrics, Henriettenstiftung, Hannover
| | - K Kittel
- Department of Gynaecology and Obstetrics, Praxisklinik, Berlin
| | - C Hanusch
- Department of Gynaecology and Obstetrics, Rot-Kreuz-Klinikum, München
| | - J Huober
- Department of Gynaecology and Obstetrics, University Hospital, Ulm
| | - C Solbach
- Department of Gynaecology and Obstetrics, University Hospital, Frankfurt
| | - C Jackisch
- Department of Gynaecology and Obstetrics, Sana-Klinikum, Offenbach
| | - G Kunz
- Department of Gynaecology and Obstetrics, St Johannes Hospital, Dortmund
| | - J U Blohmer
- Department of Gynaecology and Obstetrics, St Gertrauden-Hospital, Berlin
| | - M Hauschild
- Department of Gynaecology and Obstetrics, Hospital, Rheinfelden
| | - T Fehm
- Department of Gynaecology and Obstetrics, University Hospital, Tübingen
| | | | - B Gerber
- Department of Gynaecology and Obstetrics, University Hospital, Rostock, Germany
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Choi EY, Mazur L, Mager L, Gwon M, Pitrat D, Mulatier JC, Monnereau C, Fort A, Attias AJ, Dorkenoo K, Kwon JE, Xiao Y, Matczyszyn K, Samoc M, Kim DW, Nakao A, Heinrich B, Hashizume D, Uchiyama M, Park SY, Mathevet F, Aoyama T, Andraud C, Wu JW, Barsella A, Ribierre JC. Photophysical, amplified spontaneous emission and charge transport properties of oligofluorene derivatives in thin films. Phys Chem Chem Phys 2014; 16:16941-56. [DOI: 10.1039/c4cp01134a] [Citation(s) in RCA: 44] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
We investigate the charge transport, photophysical and amplified spontaneous emission properties of a series of monodisperse solution-processable oligofluorenes functionalized with hexyl chains at the C9 position of each fluorene unit.
Collapse
Affiliation(s)
- E. Y. Choi
- Department of Physics
- CNRS-Ewha International Research Center
- Ewha Womans University
- Seoul, South Korea
| | - L. Mazur
- Institut Parisien de Chimie Moléculaire
- Chimie des Polymères
- Université Pierre et Marie Curie
- UMR 8232
- Ivry, France
| | - L. Mager
- Institut de Physique et Chimie des Matériaux de Strasbourg (IPCMS)
- UMR 7504
- CNRS-Université de Strasbourg
- 67034 Strasbourg Cedex 2, France
| | - M. Gwon
- Department of Physics
- CNRS-Ewha International Research Center
- Ewha Womans University
- Seoul, South Korea
| | - D. Pitrat
- Laboratoire de Chimie
- CNRS-UMR 5182
- University of Lyon 1
- Ecole Normale Supérieure de Lyon
- Lyon, France
| | - J. C. Mulatier
- Laboratoire de Chimie
- CNRS-UMR 5182
- University of Lyon 1
- Ecole Normale Supérieure de Lyon
- Lyon, France
| | - C. Monnereau
- Laboratoire de Chimie
- CNRS-UMR 5182
- University of Lyon 1
- Ecole Normale Supérieure de Lyon
- Lyon, France
| | - A. Fort
- Institut de Physique et Chimie des Matériaux de Strasbourg (IPCMS)
- UMR 7504
- CNRS-Université de Strasbourg
- 67034 Strasbourg Cedex 2, France
| | - A. J. Attias
- Institut Parisien de Chimie Moléculaire
- Chimie des Polymères
- Université Pierre et Marie Curie
- UMR 8232
- Ivry, France
| | - K. Dorkenoo
- Institut de Physique et Chimie des Matériaux de Strasbourg (IPCMS)
- UMR 7504
- CNRS-Université de Strasbourg
- 67034 Strasbourg Cedex 2, France
| | - J. E. Kwon
- Department of Materials Science and Engineering
- Seoul National University
- Seoul, South Korea
| | - Y. Xiao
- Institut Parisien de Chimie Moléculaire
- Chimie des Polymères
- Université Pierre et Marie Curie
- UMR 8232
- Ivry, France
| | - K. Matczyszyn
- Institute of Physical and Theoretical Chemistry
- Wroclaw University of Technology
- 50-370 Wroclaw, Poland
| | - M. Samoc
- Institute of Physical and Theoretical Chemistry
- Wroclaw University of Technology
- 50-370 Wroclaw, Poland
| | - D.-W. Kim
- Department of Physics
- CNRS-Ewha International Research Center
- Ewha Womans University
- Seoul, South Korea
| | - A. Nakao
- Nuclear Spectroscopy Laboratory
- RIKEN Nishina Center for Accelerator-Based Science (RNC)
- Wako, Japan
| | - B. Heinrich
- Institut de Physique et Chimie des Matériaux de Strasbourg (IPCMS)
- UMR 7504
- CNRS-Université de Strasbourg
- 67034 Strasbourg Cedex 2, France
| | - D. Hashizume
- Materials Characterization Support Unit
- RIKEN Center for Emergent Matter Science (CEMS)
- Wako, Japan
| | - M. Uchiyama
- Elements Chemistry Laboratory
- RIKEN
- Wako, Japan
- Graduate School of Pharmaceutical Sciences
- The University of Tokyo
| | - S. Y. Park
- Department of Materials Science and Engineering
- Seoul National University
- Seoul, South Korea
| | - F. Mathevet
- Institut Parisien de Chimie Moléculaire
- Chimie des Polymères
- Université Pierre et Marie Curie
- UMR 8232
- Ivry, France
| | - T. Aoyama
- Elements Chemistry Laboratory
- RIKEN
- Wako, Japan
| | - C. Andraud
- Laboratoire de Chimie
- CNRS-UMR 5182
- University of Lyon 1
- Ecole Normale Supérieure de Lyon
- Lyon, France
| | - J. W. Wu
- Department of Physics
- CNRS-Ewha International Research Center
- Ewha Womans University
- Seoul, South Korea
| | - A. Barsella
- Institut de Physique et Chimie des Matériaux de Strasbourg (IPCMS)
- UMR 7504
- CNRS-Université de Strasbourg
- 67034 Strasbourg Cedex 2, France
| | - J. C. Ribierre
- Department of Physics
- CNRS-Ewha International Research Center
- Ewha Womans University
- Seoul, South Korea
| |
Collapse
|
10
|
Sun Y, Chang H, Kabatek M, Song YY, Wang Z, Jantz M, Schneider W, Wu M, Montoya E, Kardasz B, Heinrich B, te Velthuis SGE, Schultheiss H, Hoffmann A. Damping in yttrium iron garnet nanoscale films capped by platinum. Phys Rev Lett 2013; 111:106601. [PMID: 25166689 DOI: 10.1103/physrevlett.111.106601] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/07/2012] [Revised: 03/29/2013] [Indexed: 06/03/2023]
Abstract
Strong damping enhancement in nm-thick yttrium iron garnet (YIG) films due to Pt capping layers was observed. This damping is substantially larger than the expected damping due to conventional spin pumping, is accompanied by a shift in the ferromagnetic resonance field, and can be suppressed by the use of a Cu spacer in between the YIG and Pt films. The data indicate that such damping may originate from the ferromagnetic ordering in Pt atomic layers near the YIG/Pt interface and the dynamic exchange coupling between the ordered Pt spins and the spins in the YIG film.
Collapse
Affiliation(s)
- Yiyan Sun
- Department of Physics, Colorado State University, Fort Collins, Colorado 80523, USA
| | - Houchen Chang
- Department of Physics, Colorado State University, Fort Collins, Colorado 80523, USA
| | - Michael Kabatek
- Department of Physics, Colorado State University, Fort Collins, Colorado 80523, USA
| | - Young-Yeal Song
- Department of Physics, Colorado State University, Fort Collins, Colorado 80523, USA
| | - Zihui Wang
- Department of Physics, Colorado State University, Fort Collins, Colorado 80523, USA
| | - Michael Jantz
- Department of Physics, Colorado State University, Fort Collins, Colorado 80523, USA
| | - William Schneider
- Department of Physics, Colorado State University, Fort Collins, Colorado 80523, USA
| | - Mingzhong Wu
- Department of Physics, Colorado State University, Fort Collins, Colorado 80523, USA
| | - E Montoya
- Physics Department, Simon Fraser University, Burnaby, British Columbia, V5A 1S6, Canada
| | - B Kardasz
- Physics Department, Simon Fraser University, Burnaby, British Columbia, V5A 1S6, Canada
| | - B Heinrich
- Physics Department, Simon Fraser University, Burnaby, British Columbia, V5A 1S6, Canada
| | | | - Helmut Schultheiss
- Materials Science Division, Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - Axel Hoffmann
- Materials Science Division, Argonne National Laboratory, Argonne, Illinois 60439, USA
| |
Collapse
|
11
|
Rastei MV, Heinrich B, Gallani JL. Puckering stick-slip friction induced by a sliding nanoscale contact. Phys Rev Lett 2013; 111:084301. [PMID: 24010441 DOI: 10.1103/physrevlett.111.084301] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/28/2013] [Indexed: 06/02/2023]
Abstract
An atomic force microscope reveals that the sliding of a nanotip on a graphite surface occurs through a nanoscale stick-slip mechanism. The angle between the sliding direction and a stiff crystallographic axis determines the periodicity of the slip events defining domains of various friction properties. The experimental data are interpreted using the reaction rate theory, with the energy barrier driven by a local deformation of the surface and a thermally activated relaxation.
Collapse
Affiliation(s)
- M V Rastei
- Institut de Physique et Chimie des Matériaux de Strasbourg, CNRS, Université de Strasbourg, F-67034 Strasbourg, France
| | | | | |
Collapse
|
12
|
Goldstein LJ, Oliveria CT, Heinrich B, Stemmer SM, Mala C, Selder S, Bevan P, Harbeck N. Abstract P5-20-01: A randomized double-blind phase II study of the combination of oral WX-671 plus capecitabine vs. capecitabine monotherapy in first-line HER2− negative metastatic breast cancer (MBC). Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p5-20-01] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: uPA and its inhibitor PAI-1 play a key role in tumor invasion, metastasis and tumor growth. High levels of uPA and PAI-1 in breast tumors are statistically significant prognostic factors of disease-free (DFS) and overall survival (OS), which were validated at the highest level of evidence, as well as predictors for benefit of adjuvant chemotherapy. WX-UK1 is an active site competitive inhibitor of uPA with an inhibition constant in the submicromolar range. WX-671 (upamostat) is an oral prodrug of WX-UK1. In preclinical animal tumor models, both WX-UK1 and WX-671 have been shown to reduce the growth rate of implanted tumors, to inhibit invasion, and reduce metastases. This current proof of concept study is designed to substantiate the anti-metastatic properties of upamostat for patients appropriate for first line therapy for MBC.
Methods: Female patients aged >18, with HER2 negative MBC appropriate for first line monotherapy with capecitabine, with adequate performance status, organ function, bone marrow reserve without brain metastases were eligible. Patients were randomized in a double-blind fashion to receive upamostat (200mg orally daily for 21 days) plus capecitabine (1000 mg/m2 orally twice daily for 14 days) vs. capecitabine (1000 mg/m2 orally twice daily for 14 days) in 3 week treatment cycles until progressive disease or unacceptable toxicity. The primary endpoint is to evaluate the efficacy of the combination of upamostat plus capecitabine compared to monotherapy as assessed by comparison of progression free survival. The secondary objectives are OS, objective response rates, safety and tolerability, and to assess the pharmacokinetics (PK) of upamostat and capecitabine when combined.
Results: Between August 2008 and April 2011,132 patients were enrolled. 17 patients are still receiving treatment. 26% of the patients are characterized as triple negative, 13% as only Estrogen Receptor (ER) positive and 4% as only Progesteron Receptor (PR) positive. 57 % of the patients are ER and PR positive.
Conclusions: Progression free survival, response rates and safety will be reported. This abstract is being submitted as a placeholder. A completed abstract will be submitted when the analyses are completed.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P5-20-01.
Collapse
Affiliation(s)
- LJ Goldstein
- Fox Chase Cancer Center, Philadelphia, PA; Instituto Brasilerio Controle Cancer, Sao Paulo, Brazil; Hamatologisch-Onkologische-Praxis Augsburg, Augsburg, Germany; Rabin Medical Center, Petah Tikva, Israel; Wilex, Munich, Germany; Univeristy of Munich, Munich, Germany
| | - CT Oliveria
- Fox Chase Cancer Center, Philadelphia, PA; Instituto Brasilerio Controle Cancer, Sao Paulo, Brazil; Hamatologisch-Onkologische-Praxis Augsburg, Augsburg, Germany; Rabin Medical Center, Petah Tikva, Israel; Wilex, Munich, Germany; Univeristy of Munich, Munich, Germany
| | - B Heinrich
- Fox Chase Cancer Center, Philadelphia, PA; Instituto Brasilerio Controle Cancer, Sao Paulo, Brazil; Hamatologisch-Onkologische-Praxis Augsburg, Augsburg, Germany; Rabin Medical Center, Petah Tikva, Israel; Wilex, Munich, Germany; Univeristy of Munich, Munich, Germany
| | - SM Stemmer
- Fox Chase Cancer Center, Philadelphia, PA; Instituto Brasilerio Controle Cancer, Sao Paulo, Brazil; Hamatologisch-Onkologische-Praxis Augsburg, Augsburg, Germany; Rabin Medical Center, Petah Tikva, Israel; Wilex, Munich, Germany; Univeristy of Munich, Munich, Germany
| | - C Mala
- Fox Chase Cancer Center, Philadelphia, PA; Instituto Brasilerio Controle Cancer, Sao Paulo, Brazil; Hamatologisch-Onkologische-Praxis Augsburg, Augsburg, Germany; Rabin Medical Center, Petah Tikva, Israel; Wilex, Munich, Germany; Univeristy of Munich, Munich, Germany
| | - S Selder
- Fox Chase Cancer Center, Philadelphia, PA; Instituto Brasilerio Controle Cancer, Sao Paulo, Brazil; Hamatologisch-Onkologische-Praxis Augsburg, Augsburg, Germany; Rabin Medical Center, Petah Tikva, Israel; Wilex, Munich, Germany; Univeristy of Munich, Munich, Germany
| | - P Bevan
- Fox Chase Cancer Center, Philadelphia, PA; Instituto Brasilerio Controle Cancer, Sao Paulo, Brazil; Hamatologisch-Onkologische-Praxis Augsburg, Augsburg, Germany; Rabin Medical Center, Petah Tikva, Israel; Wilex, Munich, Germany; Univeristy of Munich, Munich, Germany
| | - N Harbeck
- Fox Chase Cancer Center, Philadelphia, PA; Instituto Brasilerio Controle Cancer, Sao Paulo, Brazil; Hamatologisch-Onkologische-Praxis Augsburg, Augsburg, Germany; Rabin Medical Center, Petah Tikva, Israel; Wilex, Munich, Germany; Univeristy of Munich, Munich, Germany
| |
Collapse
|
13
|
Heinrich B, From M, Cochran J, Liao LX, Celiński Z, Schneider C, Myrtle K. Studies of Exchange Coupling in Fe (001) Whisker/Cr/Fe Structures using BLS and Rheed Techniques. ACTA ACUST UNITED AC 2012. [DOI: 10.1557/proc-313-119] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
ABSTRACTThe conditions for an almost perfect growth of smooth Cr (001) films on an iron whisker substrate have been investigated by means of reflection high energy electron diffraction (RHEED). The exchange interaction between 20 Monolayer thick Fe (001) films separated from a bulk whisker Fe (001) substrate by a variable number of Cr (001) Monolayers (ML) has been investigated by means of Brillouin light scattering experiments (BLS). These experiments show unambiguously that the exchange coupling strength between the iron film and the iron whisker can be described by a short wavelength oscillatory term superposed on a slowly varying antiferromagnetic background. The BLS data enabled one to separate the bilinear and the biquadratic contributions to the antiferromagnetic exchange coupling terms. Both the bilinear and the biquadratic coupling strengths exhibited a short period oscillatory dependence on the Cr interlayer thickness (∼2 Monolayers). Maxima in the bilinear antiferromagnetic coupling strength occur for an odd number of Cr Monolayers. This observation is not in agreement with first principles calculations. The first phase inversion has been found to occur between 4 and 5 ML of Cr.
Collapse
|
14
|
Heinrich B, Arrott AS, Cochran JF, Urquhart KB, Myrtle K, Celinski Z, Zhong QM. In-Situ Techniques for Studying Epitaxially Grown Layers and Determining their Magnetic Properties. ACTA ACUST UNITED AC 2012. [DOI: 10.1557/proc-151-177] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
ABSTRACTUltrathin films of bcc Fe (001) on Ag (001) and Fe/Ni (001) bilayers on Ag were grown by molecular beam epitaxy. A wide range of surface science tools (RHEED, REELFS, AES, and XPS) were employed to establish the quality of epitaxial growth. Ferromagnetic resonance and Brillouin light scattering were used to extract the magnetic properties. Emphasis was placed on the study of magnetic anisotropies. Large uniaxial anisotropies with the easy axis perpendicular to the film surface were observed in all ultrathin structures studied. In sufficiently thin samples the saturation magnetization was oriented perpendicular to the film surface in the absence of an applied field. It has been demonstrated that in bcc Fe films the uniaxial perpendicular anisotropy originates at the film interfaces. Fe/Ni bilayers were also investigated. Ni grows in the pure bcc structure for the first 3–6ML and then transforms to a new structure which exhibits unique magnetic properties. Transformed ultrathin bilayers possesses large in-plane 4th order anisotropies far surpassing those observed in bulk Fe and Ni. The large 4th order anisotropies originate in crystallographic defects formed during the Ni lattice transformation.
Collapse
|
15
|
Karthaus M, Poddubnaya I, Churilova L, Khasanov R, Veremeychuk T, Rumyantseva E, Garin M, Brichkova O, Heinrich B, Heinemann V. Gemcitabine (G) and cisplatin (C) as first-line treatment of metastatic breast cancer (MBC): Results of phase II trial. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.27_suppl.273] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
273 Background: G has been studied in combination with a variety of agents known to be active in cancer. G has a mild toxicity profile. GC is active in various advanced tumors. Splitting of C dose (D 1 + d8) is better tolerated and can be a good alternative to once a cycle in pts with advanced breast cancer. This phase II trial evaluates G (1000 mg/m2) C (35 mg/ m2) d1+8 repeated every 21 d in the 1st-line treatment of metastatic breast cancer (MBC). The primary objective of the study was to determine the objective tumor response rate (ORR) of 1st-line GC in patients with metastatic breast cancer.The one-stage design tested the null hypothesis that the true response rate for this population should be equal to 50% for efficacy. Overall survival (OS), time to progression (TTP) and toxicity were evaluated. Methods: 70 female MBC pts with the median age of 49.8 ys (range 29.6-80.0) were enrolled. Tumor assessment was performed every other cycle by standard criteria including CT or MRI. 67 pts received a total of 310 cycles GC, out of these 54 pts were evaluable for efficacy. Results: Complete and partial responses were observed in 7/54 (13.0%) and 19/54 (35.2%) evaluable pts, respectively with an overall response of 48.2%. Disease stabilization was noticed in 19/54 (35.2%) pts. Progression was observed in 5/54 (9.3%) pts. TTP was 33.9 weeks (95% CI, 23.9-48.0). OS was 84.0 weeks (95% CI, 58.6-119.3). 1-year overall survival rate was 68.4% (95% CI, 53.6-79.3%). Hematological toxicity G4 was neutropenia in 14.9% (10/67), and no G4 thrombocytopenia. Hypotension G4 (1.5%) was the only severe non-hematological toxicity. Conclusions: GC in the first-line treatment of MBC, demonstrated a substantial overall response rate and had a good toxicity profile. GC is a suitable option for first-line MBC in selected pts.
Collapse
Affiliation(s)
- M. Karthaus
- Klinikum Neuperlach, Munich, Germany; Russian Medical Academy for Postgraduate Education, Moscow, Russia; Oncology Dispensary, Barnaul, Russia; Republic Oncology Dispensary, Kazan, Russia; Oncology Dispensary, Murmansk, Russia; Oncology Dispensary, Vladimir, Russia; Russian Cancer Research Center, Moscow, Russia; Oncology Dispensary, Saratov, Russia; Hämatologisch-onkologische-Praxis Augsburg, Augsburg, Germany; Department of Internal Medicine III, Klinikum Grosshadern, University of Munich, Munich, Germany
| | - I. Poddubnaya
- Klinikum Neuperlach, Munich, Germany; Russian Medical Academy for Postgraduate Education, Moscow, Russia; Oncology Dispensary, Barnaul, Russia; Republic Oncology Dispensary, Kazan, Russia; Oncology Dispensary, Murmansk, Russia; Oncology Dispensary, Vladimir, Russia; Russian Cancer Research Center, Moscow, Russia; Oncology Dispensary, Saratov, Russia; Hämatologisch-onkologische-Praxis Augsburg, Augsburg, Germany; Department of Internal Medicine III, Klinikum Grosshadern, University of Munich, Munich, Germany
| | - L. Churilova
- Klinikum Neuperlach, Munich, Germany; Russian Medical Academy for Postgraduate Education, Moscow, Russia; Oncology Dispensary, Barnaul, Russia; Republic Oncology Dispensary, Kazan, Russia; Oncology Dispensary, Murmansk, Russia; Oncology Dispensary, Vladimir, Russia; Russian Cancer Research Center, Moscow, Russia; Oncology Dispensary, Saratov, Russia; Hämatologisch-onkologische-Praxis Augsburg, Augsburg, Germany; Department of Internal Medicine III, Klinikum Grosshadern, University of Munich, Munich, Germany
| | - R. Khasanov
- Klinikum Neuperlach, Munich, Germany; Russian Medical Academy for Postgraduate Education, Moscow, Russia; Oncology Dispensary, Barnaul, Russia; Republic Oncology Dispensary, Kazan, Russia; Oncology Dispensary, Murmansk, Russia; Oncology Dispensary, Vladimir, Russia; Russian Cancer Research Center, Moscow, Russia; Oncology Dispensary, Saratov, Russia; Hämatologisch-onkologische-Praxis Augsburg, Augsburg, Germany; Department of Internal Medicine III, Klinikum Grosshadern, University of Munich, Munich, Germany
| | - T. Veremeychuk
- Klinikum Neuperlach, Munich, Germany; Russian Medical Academy for Postgraduate Education, Moscow, Russia; Oncology Dispensary, Barnaul, Russia; Republic Oncology Dispensary, Kazan, Russia; Oncology Dispensary, Murmansk, Russia; Oncology Dispensary, Vladimir, Russia; Russian Cancer Research Center, Moscow, Russia; Oncology Dispensary, Saratov, Russia; Hämatologisch-onkologische-Praxis Augsburg, Augsburg, Germany; Department of Internal Medicine III, Klinikum Grosshadern, University of Munich, Munich, Germany
| | - E. Rumyantseva
- Klinikum Neuperlach, Munich, Germany; Russian Medical Academy for Postgraduate Education, Moscow, Russia; Oncology Dispensary, Barnaul, Russia; Republic Oncology Dispensary, Kazan, Russia; Oncology Dispensary, Murmansk, Russia; Oncology Dispensary, Vladimir, Russia; Russian Cancer Research Center, Moscow, Russia; Oncology Dispensary, Saratov, Russia; Hämatologisch-onkologische-Praxis Augsburg, Augsburg, Germany; Department of Internal Medicine III, Klinikum Grosshadern, University of Munich, Munich, Germany
| | - M. Garin
- Klinikum Neuperlach, Munich, Germany; Russian Medical Academy for Postgraduate Education, Moscow, Russia; Oncology Dispensary, Barnaul, Russia; Republic Oncology Dispensary, Kazan, Russia; Oncology Dispensary, Murmansk, Russia; Oncology Dispensary, Vladimir, Russia; Russian Cancer Research Center, Moscow, Russia; Oncology Dispensary, Saratov, Russia; Hämatologisch-onkologische-Praxis Augsburg, Augsburg, Germany; Department of Internal Medicine III, Klinikum Grosshadern, University of Munich, Munich, Germany
| | - O. Brichkova
- Klinikum Neuperlach, Munich, Germany; Russian Medical Academy for Postgraduate Education, Moscow, Russia; Oncology Dispensary, Barnaul, Russia; Republic Oncology Dispensary, Kazan, Russia; Oncology Dispensary, Murmansk, Russia; Oncology Dispensary, Vladimir, Russia; Russian Cancer Research Center, Moscow, Russia; Oncology Dispensary, Saratov, Russia; Hämatologisch-onkologische-Praxis Augsburg, Augsburg, Germany; Department of Internal Medicine III, Klinikum Grosshadern, University of Munich, Munich, Germany
| | - B. Heinrich
- Klinikum Neuperlach, Munich, Germany; Russian Medical Academy for Postgraduate Education, Moscow, Russia; Oncology Dispensary, Barnaul, Russia; Republic Oncology Dispensary, Kazan, Russia; Oncology Dispensary, Murmansk, Russia; Oncology Dispensary, Vladimir, Russia; Russian Cancer Research Center, Moscow, Russia; Oncology Dispensary, Saratov, Russia; Hämatologisch-onkologische-Praxis Augsburg, Augsburg, Germany; Department of Internal Medicine III, Klinikum Grosshadern, University of Munich, Munich, Germany
| | - V. Heinemann
- Klinikum Neuperlach, Munich, Germany; Russian Medical Academy for Postgraduate Education, Moscow, Russia; Oncology Dispensary, Barnaul, Russia; Republic Oncology Dispensary, Kazan, Russia; Oncology Dispensary, Murmansk, Russia; Oncology Dispensary, Vladimir, Russia; Russian Cancer Research Center, Moscow, Russia; Oncology Dispensary, Saratov, Russia; Hämatologisch-onkologische-Praxis Augsburg, Augsburg, Germany; Department of Internal Medicine III, Klinikum Grosshadern, University of Munich, Munich, Germany
| |
Collapse
|
16
|
Heinrich B, Burrowes C, Montoya E, Kardasz B, Girt E, Song YY, Sun Y, Wu M. Spin pumping at the magnetic insulator (YIG)/normal metal (Au) interfaces. Phys Rev Lett 2011; 107:066604. [PMID: 21902353 DOI: 10.1103/physrevlett.107.066604] [Citation(s) in RCA: 72] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/19/2011] [Indexed: 05/20/2023]
Abstract
Spin injection across the ferrimagnetic insulator (YIG)/normal metal (Au) interface was studied by ferromagnetic resonance. The spin mixing conductance was determined by comparing the Gilbert damping in bare YIG films with those covered by a Au/Fe/Au structure. The Fe layer in Au/Fe/Au acted as a spin sink as displayed by an increased Gilbert damping parameter α compared to that in the bare YIG. In particular, for the 9.0 nm YIG/2.0 nm Au/4.3 nm Fe/6.1 nm Au structure, the YIG and Fe films were coupled by an interlayer exchange coupling, and the exchange coupled YIG exhibited an increased Gilbert damping compared to the bare YIG. This relationship between static and dynamic coupling provides direct evidence for spin pumping. The transfer of spin momentum across the YIG interface is surprisingly efficient with the spin mixing conductance g(↑↓) ≃ 1.2 × 10(14) cm(-2).
Collapse
Affiliation(s)
- B Heinrich
- Physics Department, Simon Fraser University, Burnaby, British Columbia, Canada.
| | | | | | | | | | | | | | | |
Collapse
|
17
|
Wiechno PJ, Chlosta P, Smok-Kalwat J, Pikilel J, Henry DH, Christianson DF, Somer BG, Mellado B, Duran I, Castellano DE, Callies S, Andre V, Hurt K, Lahn MMF, Stöckle M, Reuter C, Heinrich B. Interim results of a randomized phase II study with window-design to evaluate antitumor activity of the survivin antisense oligonucleotide (ASO) LY2181308 in combination with docetaxel for first-line treatment of castrate-resistant prostate cancer (CRPC). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.4592] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
18
|
Dederke B, Schumann C, Seraphin J, Wagner TOF, Rittmeyer A, Eschenburg H, Harich H, Vehling-Kaiser U, Esser M, Heinrich B. Erlotinib (Tarceva®) in der Routinebehandlung des nicht-kleinzelligen Lungenkarzinoms nach Versagen einer vorangegangenen Chemotherapie. Pneumologie 2011. [DOI: 10.1055/s-0031-1272215] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
19
|
Terazzi E, Jensen TB, Donnio B, Buchwalder K, Bourgogne C, Rogez G, Heinrich B, Gallani J, Piguet C. Control of the transition temperatures of metallomesogens by specific interface design: application to Mn12 single molecule magnets. Dalton Trans 2011; 40:12028-32. [DOI: 10.1039/c1dt10908a] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
20
|
Heinemann V, Di Gioia D, Vehling-Kaiser U, Harich HD, Heinrich B, Welt A, Ziske C, Deutsch G, Pihusch R, Kölbl H, Hegewisch-Becker S, Michl M, Stemmler HJ. A prospective multicenter phase II study of oral and i.v. vinorelbine plus trastuzumab as first-line therapy in HER2-overexpressing metastatic breast cancer. Ann Oncol 2010; 22:603-608. [PMID: 20724574 DOI: 10.1093/annonc/mdq409] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND To evaluate the efficacy and safety of oral and i.v. vinorelbine plus trastuzumab as first-line regimen in a patient-convenient application for human epidermal growth factor receptor 2 (HER2)-overexpressing patients with metastatic breast cancer. PATIENTS AND METHODS Forty-two women were enrolled in a multicenter study. The patients received i.v. vinorelbine at a dose of 25 mg/m(2) on day 1 followed by oral vinorelbine at a dose of 60 mg/m(2) on days 8 and 15 in a 3-week cycle. Standard dose trastuzumab was given at 3-week intervals. RESULTS Complete response was observed in 7 patients (18.9%) and partial response in 19 patients (51.4%), for an overall response rate of 70.3% [95% confidence interval (CI) 53.0-84.1]. The disease control rate reached 91.9% (95% CI 78.1-98.3). The median time to progression was 9.3 months, while median overall survival reached 35.6 months. Hematological and non-hematological toxic effects were acceptable with grade 3-4 leukopenia of 14% and neutropenia of 38%; cardiac toxicity did not reach the level of clinical relevance. CONCLUSION The combination of i.v. and oral vinorelbine plus trastuzumab demonstrates high activity and good tolerability in first-line treatment of HER2-overexpressing metastatic breast cancer. In addition, it offers convenience for the patients with only one i.v. treatment every 3 weeks.
Collapse
Affiliation(s)
- V Heinemann
- Medical Department III, University of Munich, Munich.
| | - D Di Gioia
- Medical Department III, University of Munich, Munich
| | | | | | | | - A Welt
- Department of Medicine (Cancer Research), West German Cancer Center, University Hospital Essen, Essen
| | - C Ziske
- Oncological Practice, Troisdorf
| | - G Deutsch
- Department of Gynecology, Diakonissenkrankenhaus Karlsruhe, Karlsruhe
| | | | - H Kölbl
- Department of Gynecology, University of Mainz, Mainz
| | | | - M Michl
- Medical Department III, University of Munich, Munich
| | - H J Stemmler
- Medical Department III, University of Munich, Munich
| |
Collapse
|
21
|
|
22
|
Abstract
At high ambient temperatures, honeybees regulate head teriperature by evaporative cooling of regurgitated honeycrop contents. Thoracic temperature is secondarily stabilized as heat flows from thorax to head by means of passive conduction and physiological facilitation resulting from accelerated blood flow. The mechanism permits flight at the extraordinarily high ambient temperature of 46 degrees C without overheating the head and thorax despite prodigious amounts of heat produced as a by-product of flight metabolism. In contrast, at low ambient temperatures, thoracic rather than head temperature is regulated; no liquid is regurgitated, and the head is heated passively by conduction both in flight and while stationary.
Collapse
|
23
|
Lander F, Heinrich B, Hufnagel M, Flügge K, Kries RV, Berner R. Invasive Infektionen durch Gruppe B-Streptokokken (Streptococcus agalactiae) bei Neugeborenen und jungen Säuglingen in Deutschland – Aktuelle Ergebnisse der laufenden ESPED-Studie. Klin Padiatr 2010. [DOI: 10.1055/s-0030-1261466] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
24
|
Lander F, Heinrich B, Hufnagel M, Flügge K, Kries RV, Berner R. Epidemiologie invasiver Infektionen durch Escherichia coli bei Neugeborenen und jungen Säuglingen in Deutschland – Aktuelle Ergebnisse der laufenden ESPED-Studie. Klin Padiatr 2010. [DOI: 10.1055/s-0030-1261467] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
25
|
Göbel U, Heinrich B, Krauth KA, Steingrüber HJ, von Kries R. [Process and outcome quality of the German Paediatric Surveillance Unit (ESPED)]. Klin Padiatr 2010; 222:92-7. [PMID: 20146163 DOI: 10.1055/s-0030-1247587] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Abstract
UNLABELLED The German paediatric surveillance unit (ESPED) was founded in 1992 with the objective to generate incidence data and to describe symptoms, diagnostic procedures, therapy and prevention for rare paediatric diseases requiring in hospital treatment. Every month the ESPED office sends a mailing card to the heads of all paediatric departments asking for the incident diagnosis of up to 12 conditions. In 2007 about 96% of the cards are returned. Each condition is represented by a principal investigator. Up till now surveillance of 52 conditions has been performed. Reports on the mailing card prompt immediate mailing of the full questionnaire. For 43 conditions the return rates were in the range of 70-100% and for 7 conditions <70% (unknown 2). The highest return rates were achieved if the principal investigator was supported by staff comprising at least two persons or if the mailing of the questionnaire was handled by the ESPED office. The scientific impact of the ESPED System was assessed by the impact factors of the journals, in which the respective ESPED studies were published. By August 31 (st) 2008 the investigators of 38 studies reported up to 7 publications per conditions surveyed. A total of 104 publications was reported: 27 of these appeared in journals without an impact factor. Among the 77 other publications 10 appeared in journals with an impact factor >10. CONCLUSION Surveillance in ESPED has contributed significantly to high quality research on rare conditions in children.
Collapse
Affiliation(s)
- U Göbel
- ESPED-Geschäftsstelle, Koordinierungszentrum für Klinische Studien, Universitätsklinikum Düsseldorf, Germany
| | | | | | | | | |
Collapse
|
26
|
Abstract
Due to the importance of using up-to-date data in information systems, this article analyzes how the data-quality dimension currency can be quantified. Based on several requirements (e.g., normalization and interpretability) and a literature review, we design a procedure to develop probability-based metrics for currency which can be adjusted to the specific characteristics of data attribute values. We evaluate the presented procedure with regard to the requirements and illustrate the applicability as well as its practical benefit. In cooperation with a major German mobile services provider, the procedure was applied in the field of campaign management in order to improve both success rates and profits.
Collapse
|
27
|
Reimer G, Brudler O, Heinrich B, Bangerter M. [EGFR (epidermal growth factor receptor) inhibitor-associated skin disorders in tumor therapy]. MMW Fortschr Med 2008; 150:37-40. [PMID: 19133368] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Affiliation(s)
- G Reimer
- Praxis für Dermatologie und Allergologie Augsburg.
| | | | | | | |
Collapse
|
28
|
Shimizu Y, Heinrich B, Guillon D, Shiro M, Monobe H, Oikawa K. Mesophase semiconductors: design for 3D-mesophases with effective paths for electronic charge hopping. Acta Crystallogr A 2008. [DOI: 10.1107/s0108767308099005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
29
|
Laessig D, Vehling-Kaiser U, Harich HD, Welt A, Heinrich B, Pihusch R, Ziske C, Deutsch G, Hegewisch-Becker S, Heinemann V. Oral and intravenous vinorelbine plus trastuzumab for 1st-line treatment of HER2-overexpressing metastatic breast cancer (MBC). A trial of the german AIO breast cancer group. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.1061] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
30
|
Heinrich B. [Fever--a cardinal symptom in medicine]. MMW Fortschr Med 2008; 150:46-51. [PMID: 18300646 DOI: 10.1007/bf03365280] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
|
31
|
Rastei MV, Heinrich B, Limot L, Ignatiev PA, Stepanyuk VS, Bruno P, Bucher JP. Size-dependent surface states of strained cobalt nanoislands on Cu(111). Phys Rev Lett 2007; 99:246102. [PMID: 18233461 DOI: 10.1103/physrevlett.99.246102] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/11/2007] [Indexed: 05/23/2023]
Abstract
Low-temperature scanning tunneling spectroscopy over Co nanoislands on Cu(111) showed that the surface states of the islands vary with their size. Occupied states exhibit a sizable downward energy shift as the island size decreases. The position of the occupied states also significantly changes across the islands. Atomic-scale simulations and ab initio calculations demonstrate that the driving force for the observed shift is related to size-dependent mesoscopic relaxations in the nanoislands.
Collapse
Affiliation(s)
- M V Rastei
- Institut de Physique et Chimie des Matériaux de Strasbourg, UMR 7504, Université Louis Pasteur, F-67034 Strasbourg, France
| | | | | | | | | | | | | |
Collapse
|
32
|
Woltersdorf G, Mosendz O, Heinrich B, Back CH. Magnetization dynamics due to pure spin currents in magnetic double layers. Phys Rev Lett 2007; 99:246603. [PMID: 18233469 DOI: 10.1103/physrevlett.99.246603] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/22/2007] [Indexed: 05/25/2023]
Abstract
The magnetization dynamics in magnetic double layers is affected by spin-pump and spin-sink effects. So far, only the spin pumping and its effect on the magnetic damping has been studied. However, due to conservation of angular momentum this spin current also leads to magnetic excitation of the layer dissipating this angular momentum. In this Letter we use time resolved magneto-optic Kerr effect to directly show the excitation due to the pure spin current. In particular, we observe magnetization dynamics due to transfer of angular momentum in magnetic double layers. In contrast to other experiments where a spin polarized charge current is passed through a nanomagnet, the effects discussed in this Letter are based on pure spin currents without net transfer of electric charge.
Collapse
|
33
|
Fassnacht M, Hahner S, Adam P, Heinrich B, Quinkler M, Stroebel P, Allolio B. Epidermal growth factor receptor (EGFR) as a potential new target in the treatment of patients with adrenocortical carcinoma: Results of pre-clinical studies. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.21025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
21025 Background: Adrenocortical carcinoma (ACC) is a rare malignancy with incompletely understood pathogenesis and poor prognosis. Overexpression of epidermal growth factor receptor (EGFR) has been demonstrated in several tumors and is partly associated with a more aggressive phenotype and a worse prognosis. In addition, targeting the EGFR tyrosine kinase represents a successful new therapeutic strategy, e.g. in non-small cell lung cancer. Therefore, we investigated the role of EGFR in ACC as a potential therapeutic target. Methods: EGFR expression was analyzed by immunohistochemistry in 115 ACCs and 5 normal adrenals using paraffin sections and tissue arrays (scoring of expression: 0–3). Utilizing the clinical data from the German ACC registry, Kaplan Meier survival analyses were performed. In 30 patients the tumor DNA was sequenced for mutations of the “hot spot” exons 19–21 of the EGFR gene. In addition, cells of the ACC cell line NCI-h295 were incubated with the EGFR antibody cetuximab (1–100 μg/ml) and cell proliferation was measured by MTT tests. Results: Immunohistochemistry revealed EGFR expression in 78% of ACCs. In 67/115 (58%) of the ACCs and 0/5 of the normal adrenals the expression level was judged as moderate-to-high (score 2 or 3). However, the expression level did not correlate with the clinical outcome in these patients. In addition, none of the sequenced tumor DNA samples showed a mutation in exons 19–21. Cetuximab exhibited a dose dependent antiproliferative effect in NCI-H295 cells (cell viability: 1μg/ml: 95±2%; 10μg/ml 90±3%*; 100 μg/ml 85±4%* vs untreated control cells: 100±3%; * = p<0.01). Conclusion: EGFR is overexpressed in the majority of ACC. Moreover, in vitro experiments demonstrated that inhibition of EGFR signalling lead to moderate growth inhibition in ACC cells. Therefore, in patients with ACC refractory to established cytotoxic therapies the experimental use of EGFR inhibitors (combined with cytotoxic therapy) seems to be justified. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- M. Fassnacht
- University Hospital of Wuerzburg, Wuerzburg, Germany; Charite Campus Mitte, Berlin, Germany; University of Heidelberg, Mannheim, Germany
| | - S. Hahner
- University Hospital of Wuerzburg, Wuerzburg, Germany; Charite Campus Mitte, Berlin, Germany; University of Heidelberg, Mannheim, Germany
| | - P. Adam
- University Hospital of Wuerzburg, Wuerzburg, Germany; Charite Campus Mitte, Berlin, Germany; University of Heidelberg, Mannheim, Germany
| | - B. Heinrich
- University Hospital of Wuerzburg, Wuerzburg, Germany; Charite Campus Mitte, Berlin, Germany; University of Heidelberg, Mannheim, Germany
| | - M. Quinkler
- University Hospital of Wuerzburg, Wuerzburg, Germany; Charite Campus Mitte, Berlin, Germany; University of Heidelberg, Mannheim, Germany
| | - P. Stroebel
- University Hospital of Wuerzburg, Wuerzburg, Germany; Charite Campus Mitte, Berlin, Germany; University of Heidelberg, Mannheim, Germany
| | - B. Allolio
- University Hospital of Wuerzburg, Wuerzburg, Germany; Charite Campus Mitte, Berlin, Germany; University of Heidelberg, Mannheim, Germany
| |
Collapse
|
34
|
Heinrich B, Hahner S, Adam P, Johanssen S, Quinkler M, Koschker AC, Stroebel P, Marx A, Allolio B, Fassnacht M. Epidermal growth factor receptor (EGFR) as a potential new target in the treatment of patients with adrenocortical carcinoma – results of pre-clinical studies. Exp Clin Endocrinol Diabetes 2007. [DOI: 10.1055/s-2007-972204] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
35
|
Guillon D, Heinrich B, Ribeiro AC, Cruz C, Nguyen HT. Thermotropic Lamellar-to-Columnar Phase Transition Exhibited by a Biforked Compound. ACTA ACUST UNITED AC 2006. [DOI: 10.1080/10587259808047105] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Affiliation(s)
- D. Guillon
- a Institut de Physiquet et de Chimie des Matériaux de Strasbourg , Groupe des Matériaux Organiques, 23, rue du Loess, F-67037 , Strasbourg Cedex , France
| | - B. Heinrich
- a Institut de Physiquet et de Chimie des Matériaux de Strasbourg , Groupe des Matériaux Organiques, 23, rue du Loess, F-67037 , Strasbourg Cedex , France
| | - A. C. Ribeiro
- a Institut de Physiquet et de Chimie des Matériaux de Strasbourg , Groupe des Matériaux Organiques, 23, rue du Loess, F-67037 , Strasbourg Cedex , France
- b Centro de Fisica da Matéria Condensada , Av. Prof. Gama Pinto 2, 1699 , Lisboa Codex , Portugal
| | - C. Cruz
- b Centro de Fisica da Matéria Condensada , Av. Prof. Gama Pinto 2, 1699 , Lisboa Codex , Portugal
| | - H. T. Nguyen
- c Centre de Recherche Paul Pascal , Avenue A. Schweitzer, 33 600 , Pessac , France
| |
Collapse
|
36
|
Heinrich B, Guillon D. Tilt Angle Variation as a Function of Chain Length and Temperature in the Smectic C Phases of p, Alkoxyphenyl-p, Alkoxybenzoates. ACTA ACUST UNITED AC 2006. [DOI: 10.1080/10587259508030990] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Affiliation(s)
- B. Heinrich
- a Institut de Physique et Chimie des Matériaux de Strasbourg, Groupe des Matériaux Organiques , 23, rue due Loess, B.P. 20CR, 67037 , STRASBOURG Cedex , France
| | - D. Guillon
- a Institut de Physique et Chimie des Matériaux de Strasbourg, Groupe des Matériaux Organiques , 23, rue due Loess, B.P. 20CR, 67037 , STRASBOURG Cedex , France
| |
Collapse
|
37
|
Affiliation(s)
- C. Cruz
- a IST-UTL , Av. Rovisco Pais, 1096 , Lisboa Codex
- b CFMC-UL , Av. Prof. Gama Pinto, 2, 1699 , Lisboa Codex , Portugal
| | - J. L. Gallani
- c IPCMS-GMO , 23 rue du Loess, BP 20CR, F-67037 , Strasburg , Cedex , France
| | - B. Heinrich
- c IPCMS-GMO , 23 rue du Loess, BP 20CR, F-67037 , Strasburg , Cedex , France
- d School of Chemistry, University of Exeter , Stocker Road, EXETER , EX4 4QD , England
| | - D. W. Bruce
- d School of Chemistry, University of Exeter , Stocker Road, EXETER , EX4 4QD , England
| | - D. Guillon
- c IPCMS-GMO , 23 rue du Loess, BP 20CR, F-67037 , Strasburg , Cedex , France
| |
Collapse
|
38
|
Stemmler HJ, Kahlert S, Siekiera W, Untch M, Heinrich B, Heinemann V. Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer. Breast 2005; 15:219-25. [PMID: 16026983 DOI: 10.1016/j.breast.2005.04.017] [Citation(s) in RCA: 125] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2004] [Revised: 04/04/2005] [Accepted: 04/13/2005] [Indexed: 11/20/2022] Open
Abstract
The intention of this retrospective analysis was to describe the characteristics of patients with brain metastasis (BM) receiving trastuzumab for HER2 overexpressing metastatic breast cancer (MBC). A specific focus was the relation of BM occurrence to remission status of visceral disease during trastuzumab treatment. Patients with MBC presenting between March 2000 and May 2004 were included in this retrospective analysis. HER2 overexpression was determined by immunohistochemistry (IHC; DAKO Hercep Test). Trastuzumab was applied at a loading dose of 4 mg/kg and a maintenance dose of 2 mg/kg. Among 136 HER2 overexpressing patients (DAKO score 3+), 42 patients with BM were identified during follow-up (30.9%). Negative hormone receptor expression (estrogen receptor (ER) and progesterone receptor (PgR)) correlated with incidence of BM (42.8% vs. 23.4%; P=0.01). There was no correlation of the development of BM with regard to tumor grading and patient age. In patients who developed BM, the median interval between visceral and brain metastasis was 14 months (range 0-69 months). At the time BM was diagnosed, 14 out of 42 patients responded to trastuzumab-based treatment schedules (OR: 33.3%, 95% CI 18.5-48.2%). Median survival from diagnosis of BM was 13 months (range 0-60 months). The median overall survival calculated from first diagnosis of metastasis was not significantly shorter in patients with BM than in patients without BM (37 vs. 47 months; P=0.07 log rank). Trastuzumab is highly effective for the treatment of liver and lung metastasis in HER2 overexpressing patients, while it is apparently ineffective for treating or preventing BM. Since one third of HER2 overexpressing patients with MBC developed BM despite effective trastuzumab treatment, new treatment strategies and closer surveillance may be warranted for these patients.
Collapse
Affiliation(s)
- H J Stemmler
- Medical Department III, University of Munich, Grosshadern, Germany.
| | | | | | | | | | | |
Collapse
|
39
|
Woltersdorf G, Buess M, Heinrich B, Back CH. Time resolved magnetization dynamics of ultrathin Fe(001) films: spin-pumping and two-magnon scattering. Phys Rev Lett 2005; 95:037401. [PMID: 16090769 DOI: 10.1103/physrevlett.95.037401] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/19/2004] [Indexed: 05/03/2023]
Abstract
The time-resolved magnetic response of ultrathin epitaxial Fe(001) films grown on GaAs(001) and covered by Au, Pd, and Cr capping layers was investigated by time and spatially resolved Kerr effect measurements. The magnetization was excited by an in-plane magnetic field pulse using the transient internal field generated at a Schottky barrier while the wavelength of the excitation (resonant mode) was roughly 4 microm. Each of the three cap layers affected the spin relaxation in a unique way. Au cap layers resulted in the bulk Gilbert damping of the Fe film. Pd cap layers caused an additional Gilbert damping due to spin-pump or spin-sink effects. Cr cap layers lead to a strong extrinsic damping which can be described by two-magnon scattering. In this case the strength of the extrinsic damping can be controlled by a field induced shift of the spin wave manifold with respect to the excited k vector.
Collapse
Affiliation(s)
- G Woltersdorf
- Simon Fraser University, 8888 University Drive, Burnaby, British Columbia V5A 1S6, Canada
| | | | | | | |
Collapse
|
40
|
Engel L, Gupta BBP, Lorenzkowski V, Heinrich B, Schwerdtle I, Gerhold S, Holthues H, Vollrath L, Spessert R. Fos-related antigen 2 (Fra-2) memorizes photoperiod in the rat pineal gland. Neuroscience 2005; 132:511-8. [PMID: 15802201 DOI: 10.1016/j.neuroscience.2004.12.014] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/16/2004] [Indexed: 11/29/2022]
Abstract
As the physiological role of fos-related antigen-2 (Fra-2) is largely unknown and since the pineal plays an important role in the photoperiodic control of the body, we have tested the hypothesis that Fra-2 expression is photoperiod-dependent and may be involved in imprinting photoperiod on the pineal gland and the body as a whole. To this end, we have investigated Fra-2 mRNA expression and Fra-2 protein expression under various light/dark (LD) cycles. A clear nocturnal increase occurs for both monitored parameters under all photoperiodic conditions studied. The level of Fra-2 protein expression clearly depends on photoperiod, because the amount of protein at dark onset and during the night negatively correlates with the length of the photoperiod. Further, high-phosphorylated Fra-2 isoforms are abundant under all photoperiods tested, with the exception of LD 20:4. Because Fra-2 phosphorylation depends on cGMP, a depressed cGMP response to adrenergic stimulation under LD 20:4 appears to explain this finding. We conclude that photoperiod is imprinted on Fra-2 in terms of both protein amount and protein phosphorylation in the rat pineal gland. This imprinting becomes fully manifest after about 7 days only, suggesting that a number of altered photoperiodic cycles are required for pineal Fra-2 to "learn" that the photoperiod has changed. Reportedly, Fra-2 limits expression of the enzyme iodothyronine deiodinase type II, which catalyzes the intracellular deiodination of thyroxine prohormone to the active 3,3',5-triiodothyronine. We have found that the extent of Fra-2 expression inversely correlates with the dII gene response to cAMP; hence the photoperiodic regulation of Fra-2 may affect the body by changing pineal thyroid hormone metabolism.
Collapse
Affiliation(s)
- L Engel
- Department of Anatomy, Johannes Gutenberg University, Saarstrasse 19-21, D-55099 Mainz, Germany
| | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Stemmler J, Kahlert S, Siekiera W, Untch M, Heinrich B, Heinemann V. Brain metastases (BM) in patients treated with trastuzumab for HER2 overexpressing metastatic breast cancer (MBC): Incidence and survival. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.1568] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- J. Stemmler
- Klin Grosshadern, Medcl Clinic III, Munich, Germany; Klin Grosshadern, Dept of Gynecology, Munich, Germany; Oncological Practice, Augsburg, Germany
| | - S. Kahlert
- Klin Grosshadern, Medcl Clinic III, Munich, Germany; Klin Grosshadern, Dept of Gynecology, Munich, Germany; Oncological Practice, Augsburg, Germany
| | - W. Siekiera
- Klin Grosshadern, Medcl Clinic III, Munich, Germany; Klin Grosshadern, Dept of Gynecology, Munich, Germany; Oncological Practice, Augsburg, Germany
| | - M. Untch
- Klin Grosshadern, Medcl Clinic III, Munich, Germany; Klin Grosshadern, Dept of Gynecology, Munich, Germany; Oncological Practice, Augsburg, Germany
| | - B. Heinrich
- Klin Grosshadern, Medcl Clinic III, Munich, Germany; Klin Grosshadern, Dept of Gynecology, Munich, Germany; Oncological Practice, Augsburg, Germany
| | - V. Heinemann
- Klin Grosshadern, Medcl Clinic III, Munich, Germany; Klin Grosshadern, Dept of Gynecology, Munich, Germany; Oncological Practice, Augsburg, Germany
| |
Collapse
|
42
|
Stamm C, Tudosa I, Siegmann HC, Stöhr J, Dobin AY, Woltersdorf G, Heinrich B, Vaterlaus A. Dissipation of spin angular momentum in magnetic switching. Phys Rev Lett 2005; 94:197603. [PMID: 16090212 DOI: 10.1103/physrevlett.94.197603] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/18/2004] [Indexed: 05/03/2023]
Abstract
Applying one ultrashort magnetic field pulse, we observe up to 10 precessional switches of the magnetization direction in single crystalline Fe films of 10 and 15 atomic layers. We find that the rate at which angular momentum is dissipated in uniform large angle spin precession increases with time and film thickness, surpassing the intrinsic ferromagnetic resonance spin lattice relaxation of Fe by nearly an order of magnitude.
Collapse
Affiliation(s)
- C Stamm
- Stanford Linear Accelerator Center, California 94309, USA.
| | | | | | | | | | | | | | | |
Collapse
|
43
|
Böttcher J, Pfeil A, Heinrich B, Lehmann G, Petrovitch A, Hansch A, Heyne JP, Mentzel HJ, Malich A, Hein G, Kaiser WA. Digital radiogrammetry as a new diagnostic tool for estimation of disease-related osteoporosis in rheumatoid arthritis compared with pQCT. Rheumatol Int 2005; 25:457-64. [PMID: 15761729 DOI: 10.1007/s00296-004-0560-z] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2004] [Accepted: 11/12/2004] [Indexed: 01/01/2023]
Abstract
OBJECTIVES To investigate the potential of a new osteogeometric technology based on digital X-ray radiogrammetry (DXR) as a diagnostic tool for quantification of severity-dependent osteoporosis, and to distinguish between inflammation-mediated and corticoid-induced variations of bone mineralisation in patients suffering from rheumatoid arthritis. METHODS Ninety-six patients (duration of disease: <18 months) underwent retrospective calculations of bone mineral density (DXR-BMD) and metacarpal index (MCI) by DXR, which were calculated from plain radiographs of the non-dominant hand. For comparison, pQCT-calculated BMD (total, cortical-subcortical and trabecular partition of bone tissue) was done on the distal radius. Severity was classified using Ratingen Score by two independent radiologists, and divided into three main groups. In addition, the patients were separated into those with corticoid medication (n=44; 5 mg/day over a half year period) and a control group (n=52) without any corticoid therapy. RESULTS Correlations between DXR-BMD and MCI versus pQCT parameters were all significant (0.36<R<0.71; p<0.01), independent of corticoid therapy. Only in the group without corticoid application, the correlation between DXR-BMD and pQCT-BMD (cortical) showed no significant association. For patients with corticoid therapy, our data revealed the lowest correlation coefficient between DXR parameters and pQCT-BMD (trabecular). Without a difference in comparison to corticoid therapy, the significant relative decrease of BMD estimated by DXR between the highest and lowest score was between 11.1% and 14.3% and for MCI between 15.8% and 17.8%. The also significant relative decrease of trabecular BMD using pQCT varied from 10.3% to 16.9%, whereas no significant results could be verified for pQCT-BMD (cortical and total). CONCLUSIONS Digital radiogrammetry can precisely estimate severity-dependent cortical reduction of bone mineral density in patients suffering from rheumatoid arthritis both with and without corticoid therapy, and seems to be able to distinguish the side effects of antirheumatic treatment from the disease-related periarticular bone loss. The detection and quantification of periarticular osteoporosis by DXR could be an important diagnostic tool in early rheumatoid arthritis.
Collapse
Affiliation(s)
- J Böttcher
- Institute of Diagnostic and Interventional Radiology, Friedrich-Schiller-University Jena, Erlanger Allee 101, 07747, Jena, Germany.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Affiliation(s)
- H Esch
- Department of Biological Sciences, University of Notre Dame, 46556, Notre Dame, Indiana, Netherlands
| | - F Goller
- Department of Biological Sciences, University of Notre Dame, 46556, Notre Dame, Indiana, Netherlands
| | - B Heinrich
- Department of Zoology, University of Vermont, 05405, Burlington, Vermont
| |
Collapse
|
45
|
Böttcher J, Pfeil A, Lehmann G, Heinrich B, Malich A, Hansch A, Petrovitch A, Mentzel HJ, Hein G, Kaiser WA. Versuch der Differenzierung zwischen kortikoidinduzierter Osteopenie und periartikul�rer Demineralisation mit Hilfe der Digitalen Radiogrammetrie (DXR) bei Patienten mit rheumatoider Arthritis. Z Rheumatol 2004; 63:473-82. [PMID: 15605213 DOI: 10.1007/s00393-004-0632-1] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2004] [Accepted: 05/10/2004] [Indexed: 01/01/2023]
Abstract
PURPOSE To investigate a new bone densitometric technology based on digital radiogrammetry (DXR) with respect to its ability to measure severity-dependent variations of bone mineral density (BMD) in patients with rheumatoid arthritis and to differentiate between corticoid-induced and periarticular bone mineral density loss. PATIENTS AND METHODS A total of 153 randomly selected patients suffering from verified rheumatoid arthritis underwent digitally performed plain radiographs of the non-dominant hand and also measurements of dual-energy X-ray absorptiometry (DXA) regarding total femur and lumbar spine in 102 patients and peripheral quantitative computed tomography (pQCT) regarding the distal radius in 51 patients. Using DXR the radiographs of the non-dominant hand were analyzed for cortical bone mineral density calculation. The severity was classified in the DXA group using the Ratingen score. Furthermore, both study populations were divided into patients with and without corticoid therapy. RESULTS Correlations between BMD determined by DXR and by DXA (R=0.44 for lumbar spine and R=0.61 for total femur) versus pQCT (0.46<R<0.59) were all significant. An appropriate association was confirmed between pQCT and DXA (R=0.61 for total femur and 0.73 for LWS). In the subgroup of patients with corticoid therapy (mean dose: 5 mg/d for a period of more than 6 month), our data showed-similar to the collective of all patients-significant correlations (0.34<R<0.59) between DXR and the other methods. In contrast to pQCT (0.37<R<0.59) the study revealed a poor association between DXR- and DXA-parameters in the subgroup of patients without corticoid therapy; only the correlation between DXA-BMD of total femur and DXR-BMD achieved a significant level (R=0.38, p<0.05). The mean value of BMD measured by DXR decreased severity dependently from 0.59 g/cm(2) (Stage 1) to 0.46 g/cm(2) (Stage 5). Similar results were verified for the metacarpal index (DXR). The relative decrease of BMD between the highest and lowest score was 21% (p<0.05). Otherwise the reduction of bone mineral density using DXA revealed no significant results. CONCLUSION The DXR-based BMD calculation can distinguish severity and progress of disease-related periarticular demineralization in contrast to those of DXA. In this context, DXA primarily measures the systemic (corticoid-induced) osteoporosis and pQCT partially estimates disease-related bone mineral density loss, whereas DXR can predominantly analyze and quantify the periarticular demineralization, which often shows a manifestation at an early stage of rheumatoid arthritis. Therefore DXR seems to be a diagnostic tool in the course of rheumatoid arthritis.
Collapse
Affiliation(s)
- J Böttcher
- Institut für Diagnostische und Interventionelle Radiologie, Friedrich-Schiller-Universität Jena, Erlanger Allee 101, 07747 Jena, Germany.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Bangerter M, Heinrich B, Brudler O. [Medical treatment of cancer in the elderly]. MMW Fortschr Med 2004; 146:30-2. [PMID: 15529665] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/01/2023]
Abstract
Paralleling increasing life expectancy, the number of cases of cancer in our population is also on the increase. The question as to whether chemotherapy for the treatment of a tumor in the elderly is appropriate or not, and if so what doses are required, depends in particular on the potentially increased toxicity of the drug in the old patient. The consequence is that alternative substances may have to be sought. When planning treatment, however, additional factors have to be taken into account, such as the possibility of differences in the physiology of the tumor in the elderly, the general state of health of the patient, the presence of concomitant diseases, possible interactions with other medications, and the patient's social environment.
Collapse
Affiliation(s)
- M Bangerter
- Hämatologisch-onkologische Gemeinschafts Praxis, Augsburg.
| | | | | |
Collapse
|
47
|
Böttcher J, Pfeil A, Lehmann G, Malich A, Petrovitch A, Heinrich B, Linß W, Kaiser WA. Notwendigkeit der Standardisierung technischer Bildparameter bei der Digitalen Radiographie (DXR). ROFO-FORTSCHR RONTG 2004. [DOI: 10.1055/s-2004-827996] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
48
|
Abstract
Melomys cervinipes Gould is one of four melomys species native to Australia. There have been no systematic surveys of parasite distribution and prevalence, or parasite community structure, for any species of Melomys. We present a comprehensive summary of the parasites of M. cervinipes by location in Queensland and northern New South Wales from published records, examination of museum specimens and data from an intensive sampling of hosts from four localities within central Queensland. An updated list prepared on the basis of these data and other published records is included.New host records include one cestode (Riallietina celebensis), one trematode (Platynosomum australiense) and 21 nematodes. Trichostrongyloid nematodes (Odilia spp.) were the dominant helminth group, with Odilia melomyos (Mawson, 1960) and O. mackerrasae (Mawson, 1960) being the core components of the helminth community. The structure of this community, with endemic and cosmopolitan elements, appears to have developed through both coevolution of hosts and parasites and host-switching events. Multidimensional scaling analysis of parasites from four central Queensland localities suggests considerable differences in community composition on a relatively small spatial scale. An island locality had a significantly different community structure and greater species diversity than nearby mainland sites. These results emphasise the importance of comparative studies of parasites among localities, and especially between island and mainland communities.
Collapse
|
49
|
Abstract
BACKGROUND Schwannomatosis is a recently recognized disorder, defined as multiple pathologically proven schwannomas without vestibular tumors diagnostic of neurofibromatosis 2 (NF2). Some investigators have questioned whether schwannomatosis is merely an attenuated form of NF2. METHODS The authors identified eight families in which a proband met their diagnostic criteria for schwannomatosis. Archived and prospectively acquired tumor specimens were studied by mutational analysis at the NF2 locus, loss of heterozygosity analysis along chromosome 22, and fluorescent in situ hybridization analysis of NF2 and the more centromeric probe BCR. Linkage analysis could be performed in six of eight families. RESULTS Clinical characterization of these kindreds showed that no affected family member harbored a vestibular tumor. Molecular analysis of 28 tumor specimens from 17 affected individuals in these kindreds revealed a pattern of somatic NF2 inactivation incompatible with our current understanding of NF2 as an inherited tumor suppressor gene syndrome. Linkage analysis excluded the NF2 locus in two kindreds, and showed a maximum lod score of 6.60 near the more centromeric marker D22S1174. CONCLUSIONS Schwannomatosis shows clinical and molecular differences from NF2 and should be considered a third major form of neurofibromatosis. Further work is needed to identify the inherited genetic element responsible for familial schwannomatosis.
Collapse
Affiliation(s)
- M MacCollin
- Department of Neurology, Massachusetts General Hospital, Charlestown, USA.
| | | | | | | | | | | | | |
Collapse
|
50
|
Kluwe L, Mautner V, Heinrich B, Dezube R, Jacoby LB, Friedrich RE, MacCollin M. Molecular study of frequency of mosaicism in neurofibromatosis 2 patients with bilateral vestibular schwannomas. J Med Genet 2003; 40:109-14. [PMID: 12566519 PMCID: PMC1735360 DOI: 10.1136/jmg.40.2.109] [Citation(s) in RCA: 104] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Neurofibromatosis 2 (NF2) is a severe autosomal dominant disorder that predisposes to multiple tumours of the nervous system. About half of all patients are founders with clinically unaffected parents. The purpose of the present study was to examine the extent to which mosaicism is present in NF2 founders. A total of 233 NF2 founders with bilateral vestibular schwannomas (BVS) were screened by exon scanning. NF2 mutations were detected in the blood samples of 122 patients (52%). In 10 of the 122 cases, the ratio of mutant to normal alleles was obviously less than 1, suggesting mosaicism. Tumour specimens were available from 35 of the 111 subjects in whom no mutation could be detected in blood specimens. Mutational analysis by exon scanning detected typical NF2 mutations in 21 of the 35 tumours. In nine subjects, the alterations found in tumours could be confirmed to be the constitutional mutation based on finding of identical mutations in pathologically and/or anatomically distinct second tumours. In six other subjects with only a single tumour available, allelic loss of the NF2 gene was found in addition to the mutation in each tumour, suggesting that either the mutation or the deletion of the NF2 gene is probably the constitutional genetic alteration. Our results suggest that failure to find constitutional mutations in blood specimen from these 15 patients was not because of the limitation of the applied screening technique, but the lack of the mutations in their leucocytes, best explained by mosaicism. Extrapolating the rate (15/35 = 43%) of mosaicism in these 35 cases to the 111 NF2 founders with no constitutional NF2 mutations found in their blood, we inferred 48 mosaic subjects (111 x 0.429). Adding the 10 mosaic cases detected directly in blood specimens, we estimate the rate of mosaicism to be 24.8% (58/233) in our cohort of 233 NF2 founders with bilateral vestibular schwannomas.
Collapse
Affiliation(s)
- L Kluwe
- Laboratory for Brain Tumour Biology, Department of Neurosurgery, University Hospital Eppendorf, Hamburg, Germany.
| | | | | | | | | | | | | |
Collapse
|